Multiple sclerosis overview: Difference between revisions

Jump to navigation Jump to search
No edit summary
m (Bot: Removing from Primary care)
 
(10 intermediate revisions by one other user not shown)
Line 1: Line 1:
<div style="-webkit-user-select: none;">
<div style="-webkit-user-select: none;">
{| style="position: fixed; top: 65%; right: 10px; margin: 0 0 0 0; border: 0; float: right;" class="infobox"
{| class="infobox" style="position: fixed; top: 65%; right: 10px; margin: 0 0 0 0; border: 0; float: right;"
|-
|-
| {{#ev:youtube|https://https://www.youtube.com/watch?v=yzH8ul5PSZ8 |350}}
| {{#ev:youtube|https://https://www.youtube.com/watch?v=yzH8ul5PSZ8 |350}}
Line 7: Line 7:
__NOTOC__
__NOTOC__
{{Template:Multiple sclerosis}}
{{Template:Multiple sclerosis}}
{{CMG}}; {{AE}} [[User:Irfan Dotani|Irfan Dotani]]
{{CMG}}; {{AE}} {{Fs}}


== Overview ==
== Overview ==
Multiple sclerosis is a [[disease]] of the [[central nervous system]] and it’s known to be multi factorial. The most common [[risk factors]] in the development of multiple sclerosis are [[smoking]], [[genetic]], [[Ethnic group|ethnic]], [[infection]], low [[vitamin D]], and [[Stress (medicine)|stress]]. Whatever the [[trigger]] is, it will lead to an acquired [[immune response]] followed by [[Inflammation|inflammatory]] reactions. These reactions lead to secretion of [[cytokines]] in the [[CNS]] [[parenchyma]] and activation of resident [[microglia]]. [[Microglia]] cells activate [[astrocytes]] to release more [[Inflammation|inflammatory]] [[cytokines]], leading to recruitment and [[Infiltration (medical)|infiltration]] of circulatory [[leukocytes]]. This burst events cause destruction of [[myelin sheath]] and forms focal sclerotic [[white matter]] plaques, which are characteristic of multiple sclerotic disease. The onset of [[symptoms]] is mostly between the age of fifteen to forty years, rarely before age fifteen or after age sixty and include [[fatigue]], [[mood]] problems, [[spasticity]], [[bowel]] and [[bladder]] [[dysfunction]], [[cognitive impairment]], [[Ophthalmoplegia|eye movement problems]], heat sensitivity, [[incoordination]], [[pain]], [[sexual dysfunction]], [[Sleep disorders|sleep disorder]], [[vertigo]] and [[visual loss]]. There is no single diagnostic study of choice for the [[Diagnosis-related group|diagnosis]] of multiple sclerosis, but multiple sclerosis can be diagnosed based on [[History and Physical examination|clinical presentation]],  [[cerebral]] plaques on [[MRI]] , and [[oligoclonal bands]] in [[CSF analysis]]. The predominant [[therapy]] for multiple sclerosis is disease-modifying treatment in relapsing-remitting multiple sclerosis,  [[Immunosuppression|immunosuppressive threpay]] in progressive multiple sclerosis and [[Glucocorticoid]] [[therapy]] in [[acute]] exacerbation.


==Historical Perspective==
==Historical Perspective==
Multiple sclerosis was first described by a [[neurologist]], Dr. Jean Martin Charcot in 1868 and named sclerose en plaque. The [[signs]] and [[symptoms]] including [[dysarthria]], [[ataxia]] and [[tremor]] were called charcot’s triad.
Multiple sclerosis was first described by a [[neurologist]], Dr. Jean Martin Charcot in 1868 and named sclerose en plaque. The [[signs]] and [[symptoms]] including [[dysarthria]], [[ataxia]] and [[tremor]] were called [[Charcot's triad|charcot’s triad]].


==Classification==
==Classification==
Multiple sclerosis may be classified into four groups according to [[clinical]] course of the [[disease]] including relapsing-remitting, secondary-progressive,  
Multiple sclerosis may be classified into four groups according to [[clinical]] course of the [[disease]] including relapsing-remitting, secondary-progressive,  
primary-progressive and progressive-relapsing<ref name=":0">Lublin FD; Reingold SC. ''Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis.'' Neurology 1996 Apr;46(4):907-11. PMID 8780061</ref>
primary-progressive and progressive-relapsing. other variants of Multiple sclerosis include clinically isolated syndrome and radiologically isolated syndrome.
 
Other variants of Multiple sclerosis include clinically isolated syndrome and radiologically isolated syndrome.<ref name="pmid24871874">{{cite journal |vauthors=Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, Wolinsky JS, Balcer LJ, Banwell B, Barkhof F, Bebo B, Calabresi PA, Clanet M, Comi G, Fox RJ, Freedman MS, Goodman AD, Inglese M, Kappos L, Kieseier BC, Lincoln JA, Lubetzki C, Miller AE, Montalban X, O'Connor PW, Petkau J, Pozzilli C, Rudick RA, Sormani MP, Stüve O, Waubant E, Polman CH |title=Defining the clinical course of multiple sclerosis: the 2013 revisions |journal=Neurology |volume=83 |issue=3 |pages=278–86 |year=2014 |pmid=24871874 |pmc=4117366 |doi=10.1212/WNL.0000000000000560 |url=}}</ref>


==Pathophysiology==
==Pathophysiology==
Multiple sclerosis is a [[disease]] of [[central nervous system]] and it’s known to be multi factorial. Whatever the trigger is, it will lead to acquired [[immune response]] followed by [[Inflammation|inflammatory]] reactions. This reactions lead to secretion of [[cytokines]] in [[CNS]] [[parenchyma]] and activation of resident [[microglia]]. [[Microglia]] cells activate [[astrocytes]] to release more [[Inflammation|inflammatory]] [[cytokines]] leading to recruitment and [[Infiltration (medical)|infiltration]] of circulatory [[leukocytes]]. This burst events cause destruction of [[myelin sheath]] and form focal sclerotic white matter plaques which are characteristic of multiple sclerotic disease.
Multiple sclerosis is a [[disease]] of the [[central nervous system]] and it’s known to be multi factorial. Whatever the trigger is, it will lead to an acquired [[immune response]] followed by [[inflammatory]] reactions. These reactions lead to secretion of [[cytokines]] in the [[CNS]] [[parenchyma]] and activation of resident [[microglia]]. [[Microglia]] cells activate [[astrocytes]] to release more [[Inflammation|inflammatory]] [[cytokines]], leading to recruitment and [[Infiltration (medical)|infiltration]] of circulatory [[leukocytes]]. This burst events cause destruction of [[myelin sheath]] and forms focal sclerotic [[white matter]] plaques, which are characteristic of multiple sclerotic disease. There is some evidence proving [[genetic]] involvement in onset of [[MS]] so that it increases the risk of developing [[MS]] from 0.1% in general population to 3% in those who have siblings with [[MS]] and 25% in those with a mono-zygote [[twin]] affected. Based on studies performed on [[post mortem]] [[brain tissue]] of patients with multiple sclerosis, there are four types of [[white matter]] lesion pathology. Damage to [[myelin sheath]] is prominent in type 1 and 2 while type 3 and 4 characteristic is dying [[Oligodendrocyte|oligodendrocytes]]. the [[etiology]] of [[Oligodendrocyte|oligodendrocytes]] death known to be multi-factorial or followed by [[hypoxia]], [[mitochondrial]] dysfunction and [[Macrophage|macrophages]].
==Causes==
==Causes==
Multiple sclerosis may be caused by different categories of causes include: [[Autoimmunity]], [[genetic]], [[infectious]] and [[Degeneration (medical)|degeneration]].
Multiple sclerosis may be caused by different categories of causes include: [[Autoimmunity]], [[genetic]], [[infectious]] and [[Degeneration (medical)|degeneration]].


==Differentiating Multiple Sclerosis from other Diseases==
==Differentiating Multiple Sclerosis from other Diseases==
Multiple sclerosis must be differentiated from other diseases that can mimic this disease [[Clinical|clinically]] or [[Radiological|radiologically]] such as [[Inflammation|Inflammatory]]/[[autoimmune]] conditions, [[Infection|Infections]],[[Metabolic]] and [[Genetic]]/Heriditary Disorders, [[CNS]] [[lymphoma]] and [[Spinal cord|spinal]] diseases.
Multiple sclerosis must be differentiated from other diseases that can mimic this disease [[Clinical|clinically]] or [[Radiological|radiologically]] such as [[systemic lupus erythematosis]], [[Sjögren’s syndrome]], [[vasculitis]], neuro-[[Behçet's disease|behçet’s disease]], [[sarcoidosis]], [[Antiphospholipid syndrome|antiphospholipid (Hughes) syndrome]] , [[Susac's syndrome|susac syndrome]], [[lyme disease]], [[syphilis]], [[HTLV-1|HTLV-1 infection]], [[HIV]]-Related Disorders of the [[CNS]], [[migraine]], [[cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy]], [[Leber's hereditary optic neuropathy|leber’s hereditary optic neuropathy]], [[vitamin B12 deficiency]], [[metachromatic leukodystrophy]], [[Fabry's disease|Fabry’s disease]], [[Krabbe disease|Krabbe’s disease]], [[adrenoleukodystrophy]], [[Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes|mitochondrial encephalopathy epilepsy lactic acidosis and stroke like episode]], [[stroke]], [[primary CNS lymphoma]] , and [[dural arteriovenous fistula]] and true malformations.


==Epidemiology and Demographics==
==Epidemiology and Demographics==
The majority of multiple sclerosis cases are reported in northern Europe, continental North America, and Australasia, which is about one of every 1000 citizens. Factors including sunlight exposure, climate, [[diet]], [[toxins]], [[genetic]] factors, geomagnetism, Childhood environmental factors and [[infections]] have been proved to cause these differences in [[MS]] prevalence. [[MS]] is at least two times more common among women than men.
The majority of multiple sclerosis cases are reported in northern Europe, continental North America, and Australasia, which is about one of every 1000 citizens. Factors including sunlight exposure, climate, [[diet]], [[toxins]], [[genetic]] factors, geomagnetism, Childhood environmental factors and [[infections]] have been proved to cause these differences in [[MS]] [[prevalence]]. [[MS]] is at least two times more common among [[women]] than [[men]]. The onset of [[symptoms]] is mostly between the age of fifteen to forty years, rarely before age fifteen or after age sixty.


==Risk Factors==
==Risk Factors==
Common [[risk factors]] in the development of multiple sclerosis are smoking, [[genetic]], [[Ethnic group|ethnic]], [[infection]], low vitamine D, and stress.
Common [[risk factors]] in the development of multiple sclerosis are [[smoking]], [[genetic]], [[Ethnic group|ethnic]], [[infection]], low [[vitamin D]], and [[stress]]. Less common [[risk factors]] in the development of multiple sclerosis include African Americans, Mexicans, Japanese, Chinese and Filipinos race and [[Epstein Barr virus|Epstein-Barr virus]].


== Natural History, Complications and Prognosis==
== Natural History, Complications and Prognosis==
Multiple sclerosis usually start between age of fifteen to forty years, rarely before age fifteen or after age sixty with symptoms such as [[optic neuritis]], [[diplopia]], [[sensory]] or motor loss, [[vertigo]] and [[Balance disorder|balance]] problems. It may be classified into four groups according to [[clinical]] course of the [[disease]] including relapsing-remitting, secondary-progressive, primary-progressive, and progressive-relapsing.<ref name="pmid8780061">{{cite journal |vauthors=Lublin FD, Reingold SC |title=Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis |journal=Neurology |volume=46 |issue=4 |pages=907–11 |date=April 1996 |pmid=8780061 |doi= |url=}}</ref> [[Complications]] that can develop as a result of mutiple sclerosis are: medication complication, [[Fatigue]]<ref name="pmid16900749">{{cite journal |vauthors=Krupp L |title=Fatigue is intrinsic to multiple sclerosis (MS) and is the most commonly reported symptom of the disease |journal=Mult. Scler. |volume=12 |issue=4 |pages=367–8 |date=August 2006 |pmid=16900749 |doi=10.1191/135248506ms1373ed |url=}}</ref>, [[mood]] problems<ref name="pmid8618657">{{cite journal |vauthors=Sadovnick AD, Remick RA, Allen J, Swartz E, Yee IM, Eisen K, Farquhar R, Hashimoto SA, Hooge J, Kastrukoff LF, Morrison W, Nelson J, Oger J, Paty DW |title=Depression and multiple sclerosis |journal=Neurology |volume=46 |issue=3 |pages=628–32 |date=March 1996 |pmid=8618657 |doi= |url=}}</ref>, [[Spasticity]]<ref name="pmid17868019">{{cite journal |vauthors=Boissy AR, Cohen JA |title=Multiple sclerosis symptom management |journal=Expert Rev Neurother |volume=7 |issue=9 |pages=1213–22 |date=September 2007 |pmid=17868019 |doi=10.1586/14737175.7.9.1213 |url=}}</ref>, [[Bowel]] and [[bladder]] dysfunction<ref name="pmid10631634">{{cite journal |vauthors=Hennessey A, Robertson NP, Swingler R, Compston DA |title=Urinary, faecal and sexual dysfunction in patients with multiple sclerosis |journal=J. Neurol. |volume=246 |issue=11 |pages=1027–32 |date=November 1999 |pmid=10631634 |doi= |url=}}</ref>, [[Cognitive impairment]]<ref name="pmid12640060">{{cite journal |vauthors=Achiron A, Barak Y |title=Cognitive impairment in probable multiple sclerosis |journal=J. Neurol. Neurosurg. Psychiatry |volume=74 |issue=4 |pages=443–6 |date=April 2003 |pmid=12640060 |pmc=1738365 |doi= |url=}}</ref><ref name="pmid15774439">{{cite journal |vauthors=Deloire MS, Salort E, Bonnet M, Arimone Y, Boudineau M, Amieva H, Barroso B, Ouallet JC, Pachai C, Galliaud E, Petry KG, Dousset V, Fabrigoule C, Brochet B |title=Cognitive impairment as marker of diffuse brain abnormalities in early relapsing remitting multiple sclerosis |journal=J. Neurol. Neurosurg. Psychiatry |volume=76 |issue=4 |pages=519–26 |date=April 2005 |pmid=15774439 |pmc=1739602 |doi=10.1136/jnnp.2004.045872 |url=}}</ref><ref name="pmid2027484">{{cite journal |vauthors=Rao SM, Leo GJ, Bernardin L, Unverzagt F |title=Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction |journal=Neurology |volume=41 |issue=5 |pages=685–91 |date=May 1991 |pmid=2027484 |doi= |url=}}</ref><ref name="pmid15277630">{{cite journal |vauthors=Huijbregts SC, Kalkers NF, de Sonneville LM, de Groot V, Reuling IE, Polman CH |title=Differences in cognitive impairment of relapsing remitting, secondary, and primary progressive MS |journal=Neurology |volume=63 |issue=2 |pages=335–9 |date=July 2004 |pmid=15277630 |doi= |url=}}</ref>, Heat sensitivity.<ref name="pmid7550931">{{cite journal |vauthors=Selhorst JB, Saul RF |title=Uhthoff and his symptom |journal=J Neuroophthalmol |volume=15 |issue=2 |pages=63–9 |date=June 1995 |pmid=7550931 |doi= |url=}}</ref>, [[Incoordination]]<ref name="pmid25573524">{{cite journal |vauthors=Rinker JR, Salter AR, Walker H, Amara A, Meador W, Cutter GR |title=Prevalence and characteristics of tremor in the NARCOMS multiple sclerosis registry: a cross-sectional survey |journal=BMJ Open |volume=5 |issue=1 |pages=e006714 |date=January 2015 |pmid=25573524 |pmc=4289717 |doi=10.1136/bmjopen-2014-006714 |url=}}</ref>, [[Pain]]<ref name="pmid26087108">{{cite journal |vauthors=Drulovic J, Basic-Kes V, Grgic S, Vojinovic S, Dincic E, Toncev G, Kezic MG, Kisic-Tepavcevic D, Dujmovic I, Mesaros S, Miletic-Drakulic S, Pekmezovic T |title=The Prevalence of Pain in Adults with Multiple Sclerosis: A Multicenter Cross-Sectional Survey |journal=Pain Med |volume=16 |issue=8 |pages=1597–602 |date=August 2015 |pmid=26087108 |doi=10.1111/pme.12731 |url=}}</ref><ref name="pmid23318126">{{cite journal |vauthors=Foley PL, Vesterinen HM, Laird BJ, Sena ES, Colvin LA, Chandran S, MacLeod MR, Fallon MT |title=Prevalence and natural history of pain in adults with multiple sclerosis: systematic review and meta-analysis |journal=Pain |volume=154 |issue=5 |pages=632–42 |date=May 2013 |pmid=23318126 |doi=10.1016/j.pain.2012.12.002 |url=}}</ref>, [[Sexual dysfunction]]<ref name="pmid26003254">{{cite journal |vauthors=Lew-Starowicz M, Gianotten WL |title=Sexual dysfunction in patients with multiple sclerosis |journal=Handb Clin Neurol |volume=130 |issue= |pages=357–70 |date=2015 |pmid=26003254 |doi=10.1016/B978-0-444-63247-0.00020-1 |url=}}</ref><ref name="pmid10618700">{{cite journal |vauthors=Zivadinov R, Zorzon M, Bosco A, Bragadin LM, Moretti R, Bonfigli L, Iona LG, Cazzato G |title=Sexual dysfunction in multiple sclerosis: II. Correlation analysis |journal=Mult. Scler. |volume=5 |issue=6 |pages=428–31 |date=December 1999 |pmid=10618700 |doi=10.1177/135245859900500i610 |url=}}</ref>, Sleep disorders<ref name="pmid17942519">{{cite journal |vauthors=Manconi M, Rocca MA, Ferini-Strambi L, Tortorella P, Agosta F, Comi G, Filippi M |title=Restless legs syndrome is a common finding in multiple sclerosis and correlates with cervical cord damage |journal=Mult. Scler. |volume=14 |issue=1 |pages=86–93 |date=January 2008 |pmid=17942519 |doi=10.1177/1352458507080734 |url=}}</ref><ref name="pmid8787103">{{cite journal |vauthors=Amarenco G, Kerdraon J, Denys P |title=[Bladder and sphincter disorders in multiple sclerosis. Clinical, urodynamic and neurophysiological study of 225 cases] |language=French |journal=Rev. Neurol. (Paris) |volume=151 |issue=12 |pages=722–30 |date=December 1995 |pmid=8787103 |doi= |url=}}</ref><ref name="pmid23078359">{{cite journal |vauthors=Schürks M, Bussfeld P |title=Multiple sclerosis and restless legs syndrome: a systematic review and meta-analysis |journal=Eur. J. Neurol. |volume=20 |issue=4 |pages=605–15 |date=April 2013 |pmid=23078359 |doi=10.1111/j.1468-1331.2012.03873.x |url=}}</ref>, [[vertigo]]<ref name="pmid11094117">{{cite journal |vauthors=Frohman EM, Zhang H, Dewey RB, Hawker KS, Racke MK, Frohman TC |title=Vertigo in MS: utility of positional and particle repositioning maneuvers |journal=Neurology |volume=55 |issue=10 |pages=1566–9 |date=November 2000 |pmid=11094117 |doi= |url=}}</ref>, [[visual loss]]<ref name="pmid16554529">{{cite journal |vauthors=Balcer LJ |title=Clinical practice. Optic neuritis |journal=N. Engl. J. Med. |volume=354 |issue=12 |pages=1273–80 |date=March 2006 |pmid=16554529 |doi=10.1056/NEJMcp053247 |url=}}</ref>. there are some factors associated with a particularly poor [[prognosis]] among [[patients]] with multiple sclerosis such as: Relapsing versus progressive disease<ref name="pmid8017890">{{cite journal |vauthors=Weinshenker BG |title=Natural history of multiple sclerosis |journal=Ann. Neurol. |volume=36 Suppl |issue= |pages=S6–11 |date=1994 |pmid=8017890 |doi= |url=}}</ref><ref name="pmid11078767">{{cite journal |vauthors=Confavreux C, Vukusic S, Moreau T, Adeleine P |title=Relapses and progression of disability in multiple sclerosis |journal=N. Engl. J. Med. |volume=343 |issue=20 |pages=1430–8 |date=November 2000 |pmid=11078767 |doi=10.1056/NEJM200011163432001 |url=}}</ref><ref name="pmid16434648">{{cite journal |vauthors=Tremlett H, Paty D, Devonshire V |title=Disability progression in multiple sclerosis is slower than previously reported |journal=Neurology |volume=66 |issue=2 |pages=172–7 |date=January 2006 |pmid=16434648 |doi=10.1212/01.wnl.0000194259.90286.fe |url=}}</ref>, early symptoms<ref name="pmid17172607">{{cite journal |vauthors=Langer-Gould A, Popat RA, Huang SM, Cobb K, Fontoura P, Gould MK, Nelson LM |title=Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review |journal=Arch. Neurol. |volume=63 |issue=12 |pages=1686–91 |date=December 2006 |pmid=17172607 |doi=10.1001/archneur.63.12.1686 |url=}}</ref>, Demographics<ref name="pmid15596747">{{cite journal |vauthors=Cree BA, Khan O, Bourdette D, Goodin DS, Cohen JA, Marrie RA, Glidden D, Weinstock-Guttman B, Reich D, Patterson N, Haines JL, Pericak-Vance M, DeLoa C, Oksenberg JR, Hauser SL |title=Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis |journal=Neurology |volume=63 |issue=11 |pages=2039–45 |date=December 2004 |pmid=15596747 |doi= |url=}}</ref>, Sex<ref name="pmid8017890" />, Smoking<ref name="pmid23628463">{{cite journal |vauthors=Roudbari SA, Ansar MM, Yousefzad A |title=Smoking as a risk factor for development of Secondary Progressive Multiple Sclerosis: A study in IRAN, Guilan |journal=J. Neurol. Sci. |volume=330 |issue=1-2 |pages=52–5 |date=July 2013 |pmid=23628463 |doi=10.1016/j.jns.2013.04.003 |url=}}</ref>.
Multiple sclerosis usually start between age of fifteen to forty years, rarely before age fifteen or after age sixty with [[symptoms]] such as [[optic neuritis]], [[diplopia]], [[Sensory loss|sensory]] or [[Muscle weakness|motor loss]], [[vertigo]] and [[Balance disorder|balance]] problems. It may be classified into four groups according to [[clinical]] course of the [[disease]] including relapsing-remitting, secondary-progressive, primary-progressive, and progressive-relapsing. [[Complications]] that can develop as a result of multiple sclerosis are: [[medication]] [[complication]], [[Fatigue]], [[mood]] problems, [[Spasticity]], [[Bowel]] and [[bladder]] dysfunction, [[Cognitive impairment]], Heat sensitivity., [[Incoordination]], [[Pain]], [[Sexual dysfunction]], [[Sleep disorder|Sleep disorders]], [[vertigo]], [[visual loss]]. there are some factors associated with a particularly poor [[prognosis]] among [[patients]] with multiple sclerosis such as: Relapsing versus progressive disease, early symptoms, Demographics, Sex, [[Smoking]].


== Diagnosis ==
== Diagnosis ==
=== Diagnostic Study of choice ===
There is no single diagnostic study of choice for the [[diagnosis]] of multiple sclerosis, but multiple sclerosis can be diagnosed based on [[History and Physical examination|clinical presentation]], [[MRI]] findings, and [[CSF analysis]]. Sequence of diagnostic studies are [[History and Physical examination|history and physical examination]], [[imaging]], and [[CSF analysis]]. The findings are [[cerebral]] plaques which are [[demyelinating]] areas on [[MRI]] and an elevated concentration of [[CSF]] [[oligoclonal bands]]. The diagnostic criteria for multiple sclerosis is [[McDonald criteria]].
===History and Symptoms===
===History and Symptoms===
The most common [[symptoms]] of multiple sclerosis include: [[Fatigue]], [[mood]] problems, [[spasticity]], [[bowel]] and [[bladder]] dysfunction, [[cognitive impairment]], eye movement problems, heat sensitivity, [[incoordination]], [[pain]], [[sexual dysfunction]], [[Sleep disorders|sleep disorder]], [[vertigo]] and [[visual loss]].
The most common [[symptoms]] of multiple sclerosis include: [[Fatigue]], [[Mood disorder|mood problems]], [[spasticity]], [[bowel]] and [[bladder]] dysfunction, [[cognitive impairment]], [[Ophthalmoplegia|eye movement problems]], heat sensitivity, [[incoordination]], [[pain]], [[sexual dysfunction]], [[Sleep disorders|sleep disorder]], [[vertigo]] and [[visual loss]].


=== Physical Examination ===
=== Physical Examination ===
[[Physical examination]] of patients with multiple sclerosis is usually remarkable for [[lhermitte's sign]], [[spasticity]] and increased [[reflexes]], [[internuclear ophthalmoplegia]], [[optic neuritis]] and [[gait disturbance]].
[[Physical examination]] of patients with multiple sclerosis is usually remarkable for [[lhermitte's sign]], [[spasticity]], increased [[reflexes]], [[internuclear ophthalmoplegia]], [[optic neuritis]], [[gait disturbance]], and [[urinary incontinence]].


=== Laboratory Findings ===
=== Laboratory Findings ===
An elevated concentration of [[CSF]] [[oligoclonal bands]] is [[diagnostic]] of multiple sclerosis.
An elevated concentration of [[CSF]] [[oligoclonal bands]] is [[diagnostic]] of multiple sclerosis.


===Imaging Findings===
=== Electrocardiogram ===
On [[MRI]], multiple sclerosis is characterized by [[cerebral]] plaques which are [[demyelinating]] areas. These [[Lesion|lesions]] are commonly ovoid and located in periventricular [[white matter]], [[cerebellum]], and [[brain stem]]. These lesions are hyperintense on T2 sections of [[MRI]] enhanced [[lesions]] in double delayed high dose [[CT scan]] may be helpful in the [[diagnosis]] of multiple sclerosis.
An [[ECG]] may be helpful in the [[diagnosis]] of multiple sclerosis. Findings on an [[ECG]] suggestive of multiple sclerosis include [[atrial fibrillation]], [[ventricular arrhythmia]], shortened or [[Long PR interval|longed P-R interval]], tall waves or peaked waves, [[U waves]], and [[Q waves]].
 
=== X-ray ===
There are no [[x-ray]] findings associated with multiple sclerosis.
 
=== Echocardiography and Ultrasound ===
There are no [[echocardiography]]/[[ultrasound]] findings associated with multiple sclerosis.
 
=== CT scan ===
Findings on [[CT scan]] suggestive of multiple sclerosis include [[brain atrophy]] and some contrast enhancing plaques. Findings on an Double delayed high dose CT scan suggestive of Multiple sclerosis include enhanced [[lesions]] in double delayed high dose [[CT scan]] which are indicators of [[blood brain barrier]] disruption.
 
=== MRI ===
On [[MRI]], multiple sclerosis is characterized by [[cerebral]] plaques disseminating in space and time which are characteristic of [[demyelinating]] areas. These [[Lesion|lesions]] are commonly void, and located in periventricular [[white matter]], [[cerebellum]], and the [[brain stem]]. These lesions are hyperintense on T2 sections of a [[MRI]].
 
=== Other Imaging Findings ===
There is no other [[imaging]] findings associated with multiple sclerosis.


=== Other Diagnostic Studies ===
=== Other Diagnostic Studies ===
[[Visual evoked potential|visual evoked potential studies]] and anti[[myelin]] [[antibodies]] may be helpful in the [[diagnosis]] of multiple sclerosis.
[[Visual evoked potential|Visual evoked potential studies]], anti[[myelin]] [[antibodies]], and optimal coherence tomography may be helpful in the [[diagnosis]] of multiple sclerosis.


==Treatment==
==Treatment==
Line 61: Line 79:


=== Alternative Therapies ===
=== Alternative Therapies ===
Alternative treatments for multiple sclerosis are: [[Diet (nutrition)|Dietary]] regimens [[herbal medicine]] ( [[marijuana]] ) [[hyperbaric oxygenation]] [[Martial arts therapy|therapeutic practice of martial arts.]]
Alternative [[treatments]] for multiple sclerosis are: [[Diet (nutrition)|Dietary]] regimens [[herbal medicine]] ( [[marijuana]] ) [[hyperbaric oxygenation]] [[Martial arts therapy|therapeutic practice of martial arts.]]


=== Prevention ===
=== Primary Prevention ===
Primary: Effective measures for the [[primary prevention]] of multiple sclerosis include: [[Vitamin D]] supplement, [[smoking]] cessation, early exposure to [[infection]].
Effective measures for the [[primary prevention]] of multiple sclerosis include: [[Vitamin D]] supplement, [[smoking]] cessation, early exposure to [[infection]]<nowiki/>s.


Secondary: There is no established method for [[secondary prevention]] of multiple sclerosis.
=== Secondary Prevention ===
There is no established method for [[secondary prevention]] of multiple sclerosis.


=== Tertiary Prevention ===
Tertiary: There is strong evidence that [[exercise]] therapy can improve [[muscle]] function and [[mobility]] in multiple sclerosis patients.
Tertiary: There is strong evidence that [[exercise]] therapy can improve [[muscle]] function and [[mobility]] in multiple sclerosis patients.


==References==
==References==
{{reflist|2}}
{{reflist|2}}
{{WH}}
{{WS}}


[[Category:Primary care]]
[[Category:Neurology]]
[[Category:Neurology]]
[[Category:Orthopedics]]
[[Category:Orthopedics]]
[[Category:Rheumatology]]
[[Category:Rheumatology]]
{{WH}}
{{WS}}

Latest revision as of 22:48, 29 July 2020

https://https://www.youtube.com/watch?v=yzH8ul5PSZ8 |350}}

Multiple sclerosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Multiple sclerosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography or Ultrasound

CT Scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Alternative Therapies

Primary Prevention

Secondary Prevention

Tertiary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Multiple sclerosis overview On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Multiple sclerosis overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Multiple sclerosis overview

CDC on Multiple sclerosis overview

Multiple sclerosis overview in the news

Blogs on Multiple sclerosis overview

Directions to Hospitals Treating Multiple sclerosis

Risk calculators and risk factors for Multiple sclerosis overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.

Overview

Multiple sclerosis is a disease of the central nervous system and it’s known to be multi factorial. The most common risk factors in the development of multiple sclerosis are smoking, genetic, ethnic, infection, low vitamin D, and stress. Whatever the trigger is, it will lead to an acquired immune response followed by inflammatory reactions. These reactions lead to secretion of cytokines in the CNS parenchyma and activation of resident microglia. Microglia cells activate astrocytes to release more inflammatory cytokines, leading to recruitment and infiltration of circulatory leukocytes. This burst events cause destruction of myelin sheath and forms focal sclerotic white matter plaques, which are characteristic of multiple sclerotic disease. The onset of symptoms is mostly between the age of fifteen to forty years, rarely before age fifteen or after age sixty and include fatigue, mood problems, spasticity, bowel and bladder dysfunction, cognitive impairment, eye movement problems, heat sensitivity, incoordination, pain, sexual dysfunction, sleep disorder, vertigo and visual loss. There is no single diagnostic study of choice for the diagnosis of multiple sclerosis, but multiple sclerosis can be diagnosed based on clinical presentation, cerebral plaques on MRI , and oligoclonal bands in CSF analysis. The predominant therapy for multiple sclerosis is disease-modifying treatment in relapsing-remitting multiple sclerosis, immunosuppressive threpay in progressive multiple sclerosis and Glucocorticoid therapy in acute exacerbation.

Historical Perspective

Multiple sclerosis was first described by a neurologist, Dr. Jean Martin Charcot in 1868 and named sclerose en plaque. The signs and symptoms including dysarthria, ataxia and tremor were called charcot’s triad.

Classification

Multiple sclerosis may be classified into four groups according to clinical course of the disease including relapsing-remitting, secondary-progressive, primary-progressive and progressive-relapsing. other variants of Multiple sclerosis include clinically isolated syndrome and radiologically isolated syndrome.

Pathophysiology

Multiple sclerosis is a disease of the central nervous system and it’s known to be multi factorial. Whatever the trigger is, it will lead to an acquired immune response followed by inflammatory reactions. These reactions lead to secretion of cytokines in the CNS parenchyma and activation of resident microglia. Microglia cells activate astrocytes to release more inflammatory cytokines, leading to recruitment and infiltration of circulatory leukocytes. This burst events cause destruction of myelin sheath and forms focal sclerotic white matter plaques, which are characteristic of multiple sclerotic disease. There is some evidence proving genetic involvement in onset of MS so that it increases the risk of developing MS from 0.1% in general population to 3% in those who have siblings with MS and 25% in those with a mono-zygote twin affected. Based on studies performed on post mortem brain tissue of patients with multiple sclerosis, there are four types of white matter lesion pathology. Damage to myelin sheath is prominent in type 1 and 2 while type 3 and 4 characteristic is dying oligodendrocytes. the etiology of oligodendrocytes death known to be multi-factorial or followed by hypoxia, mitochondrial dysfunction and macrophages.

Causes

Multiple sclerosis may be caused by different categories of causes include: Autoimmunity, genetic, infectious and degeneration.

Differentiating Multiple Sclerosis from other Diseases

Multiple sclerosis must be differentiated from other diseases that can mimic this disease clinically or radiologically such as systemic lupus erythematosis, Sjögren’s syndrome, vasculitis, neuro-behçet’s disease, sarcoidosis, antiphospholipid (Hughes) syndrome , susac syndrome, lyme disease, syphilis, HTLV-1 infection, HIV-Related Disorders of the CNS, migraine, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy, leber’s hereditary optic neuropathy, vitamin B12 deficiency, metachromatic leukodystrophy, Fabry’s disease, Krabbe’s disease, adrenoleukodystrophy, mitochondrial encephalopathy epilepsy lactic acidosis and stroke like episode, stroke, primary CNS lymphoma , and dural arteriovenous fistula and true malformations.

Epidemiology and Demographics

The majority of multiple sclerosis cases are reported in northern Europe, continental North America, and Australasia, which is about one of every 1000 citizens. Factors including sunlight exposure, climate, diet, toxins, genetic factors, geomagnetism, Childhood environmental factors and infections have been proved to cause these differences in MS prevalence. MS is at least two times more common among women than men. The onset of symptoms is mostly between the age of fifteen to forty years, rarely before age fifteen or after age sixty.

Risk Factors

Common risk factors in the development of multiple sclerosis are smoking, genetic, ethnic, infection, low vitamin D, and stress. Less common risk factors in the development of multiple sclerosis include African Americans, Mexicans, Japanese, Chinese and Filipinos race and Epstein-Barr virus.

Natural History, Complications and Prognosis

Multiple sclerosis usually start between age of fifteen to forty years, rarely before age fifteen or after age sixty with symptoms such as optic neuritis, diplopia, sensory or motor loss, vertigo and balance problems. It may be classified into four groups according to clinical course of the disease including relapsing-remitting, secondary-progressive, primary-progressive, and progressive-relapsing. Complications that can develop as a result of multiple sclerosis are: medication complication, Fatigue, mood problems, Spasticity, Bowel and bladder dysfunction, Cognitive impairment, Heat sensitivity., Incoordination, Pain, Sexual dysfunction, Sleep disorders, vertigo, visual loss. there are some factors associated with a particularly poor prognosis among patients with multiple sclerosis such as: Relapsing versus progressive disease, early symptoms, Demographics, Sex, Smoking.

Diagnosis

Diagnostic Study of choice

There is no single diagnostic study of choice for the diagnosis of multiple sclerosis, but multiple sclerosis can be diagnosed based on clinical presentation, MRI findings, and CSF analysis. Sequence of diagnostic studies are history and physical examination, imaging, and CSF analysis. The findings are cerebral plaques which are demyelinating areas on MRI and an elevated concentration of CSF oligoclonal bands. The diagnostic criteria for multiple sclerosis is McDonald criteria.

History and Symptoms

The most common symptoms of multiple sclerosis include: Fatigue, mood problems, spasticity, bowel and bladder dysfunction, cognitive impairment, eye movement problems, heat sensitivity, incoordination, pain, sexual dysfunction, sleep disorder, vertigo and visual loss.

Physical Examination

Physical examination of patients with multiple sclerosis is usually remarkable for lhermitte's sign, spasticity, increased reflexes, internuclear ophthalmoplegia, optic neuritis, gait disturbance, and urinary incontinence.

Laboratory Findings

An elevated concentration of CSF oligoclonal bands is diagnostic of multiple sclerosis.

Electrocardiogram

An ECG may be helpful in the diagnosis of multiple sclerosis. Findings on an ECG suggestive of multiple sclerosis include atrial fibrillation, ventricular arrhythmia, shortened or longed P-R interval, tall waves or peaked waves, U waves, and Q waves.

X-ray

There are no x-ray findings associated with multiple sclerosis.

Echocardiography and Ultrasound

There are no echocardiography/ultrasound findings associated with multiple sclerosis.

CT scan

Findings on CT scan suggestive of multiple sclerosis include brain atrophy and some contrast enhancing plaques. Findings on an Double delayed high dose CT scan suggestive of Multiple sclerosis include enhanced lesions in double delayed high dose CT scan which are indicators of blood brain barrier disruption.

MRI

On MRI, multiple sclerosis is characterized by cerebral plaques disseminating in space and time which are characteristic of demyelinating areas. These lesions are commonly void, and located in periventricular white matter, cerebellum, and the brain stem. These lesions are hyperintense on T2 sections of a MRI.

Other Imaging Findings

There is no other imaging findings associated with multiple sclerosis.

Other Diagnostic Studies

Visual evoked potential studies, antimyelin antibodies, and optimal coherence tomography may be helpful in the diagnosis of multiple sclerosis.

Treatment

Medical Therapy

The predominant therapy for multiple sclerosis is disease-modifying treatment in relapsing-remitting multiple sclerosis, immunosuppressive threpay in progressive multiple sclerosis and Glucocorticoid therapy in acute exacerbation.

Surgery

Surgery can be helpful in controlling trigeminal neuralgia, tremor, and ataxia.

Alternative Therapies

Alternative treatments for multiple sclerosis are: Dietary regimens herbal medicine ( marijuana ) hyperbaric oxygenation therapeutic practice of martial arts.

Primary Prevention

Effective measures for the primary prevention of multiple sclerosis include: Vitamin D supplement, smoking cessation, early exposure to infections.

Secondary Prevention

There is no established method for secondary prevention of multiple sclerosis.

Tertiary Prevention

Tertiary: There is strong evidence that exercise therapy can improve muscle function and mobility in multiple sclerosis patients.

References

Template:WH Template:WS